Why This Strategist Sees Only 3 Buyable U.S. Stocks at the Start of 2026

At the outset of 2026, most market strategists remain optimistic about U.S. equities, citing resilient economic growth, strong corporate earnings, and contained inflation. However, Jeffrey Yale Rubin, president and CIO of Birinyi Associates, takes a much more cautious stance, describing himself as a “cautious calf” rather than a full‑on bull. Rubin’s hesitation stems from weak market breadth — he observes that the majority of stocks in the S&P 500 lack sustained buying momentum, with most showing neutral money flows rather than clear accumulation. Rubin’s analysis highlights that only 28 stocks are under accumulation compared with 401 neutral and a noticeable share in distribution — indicating limited strength to drive broader market advances. Among the stocks in uptrends, just four meet his criteria for both momentum and accumulation: Tesla, Eli Lilly, Analog Devices, and Qualcomm. But due to Tesla’s extremely high valuation (trading near 270 times 2026 earnings forecasts), Rubin excludes it from his list, leaving only three truly “buyable” names by his standards. Rubin also downplays valuation fears such as high cyclically adjusted P/E (CAPE), arguing that they have historically signaled caution without derailing long market runs — and he continues to see economic fundamentals as supportive. Still, absent broader participation from a wider range of stocks, he remains reluctant to be broadly bullish at the start of 2026. #USStocks #MarketStrategy #InvestingInsights #StockMarket2026 #SlimScan #GrowthStocks #CANSLIM